Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder - 2How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- 3Partner of crime boss Steven Lyons arrested in Dubai
- 4'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- 5Best Disney Palace: Which One Catches Your Creative mind?
- Gartex Texprocess India to showcase innovations across textile ecosystem
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Esteem Stuffed Gaming Workstations to Consider
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
